Track Categories

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

Cancer can occur anywhere in the body. The continuous growth of tumor cells can affect organ which can be lung, prostate, colon, rectum, stomach, liver, cervix, breast. Cancer are often described by the body part that they originated from. However, some body parts contain multiple types of tissue, so to be precise, cancer can be additionally classified by the type of cell that the tumor cells originated from. The type of cancer a person has needed to be known properly as diverse types of cancer can behave very differently and respond to different treatments. In that colorectal cancer is one of the organ specific cancer which begins with polyps which can be seen on the inner lining of colon or rectum and are further categorised based on polyps.

  • Track 1-1Adenomatous Polyps
  • Track 1-2 Hyperplastic Polyps
  • Track 1-3Dysplasia
  • Track 1-4Bowel Cancer
  • Track 1-5Rectal cancer
  • Track 1-6Colon cancer
  • Track 1-7 Adenocarcinomas
  • Track 1-8Gastrointestinal stromal tumors (GISTs)

Colorectal cancer are associated with hints or syndromes knowing them early can reduce the risk and can be prevented. One of the early clue of colorectal cancer is bleeding. The colorectal cancer depends on the position of the tumor in the bowel, and whether it has spread anywhere in the body. A routine screening must be carried to detect the presence of the colorectal cancer tumor and especially for aged people above 50 it is considered bit sensitive as they are more prone to get this disease because of the weak bowel system.  


  • Track 2-1Change in bowel habits
  • Track 2-2Blood in the stool
  • Track 2-3Anemia
  • Track 2-4Abdominal pain
  • Track 2-5Weight loss
  • Track 2-6Vomiting
  • Track 2-7 Diarrhea
  • Track 2-8Constipation

Colorectal Screening give a complete analysis of colon cancer screening, from epidemiology, to the present-day screening techniques such as stool DNA, Narrow Band Imaging, High Definition Colonoscopies and Computerized Tomography (CT) Colonography. Colorectal cancer almost always grows from precancerous polyps (abnormal growths) in the colon or rectum. Screening techniques can find precancerous polyps, so that they can be removed before they turn into cancer. Screening tests can also find colorectal cancer quick, when treatment works best.


  • Track 3-1Flexible Sigmoidoscopy
  • Track 3-2CT Colonography (Virtual Colonoscopy)
  • Track 3-3Stool DNA test (FIT-DNA)
  • Track 3-4Colonoscopy
  • Track 3-5Double-contrast barium enema

Radiation therapy is not a common way to treat colon cancer, though it may be used in certain circumstances. Radiation therapy, with chemotherapy, is frequently used in the adjuvant or neoadjuvant setting for the treatment of rectal cancers, whereas chemotherapy alone is more common for the auxiliary and neoadjuvant treatment of colon cancers. Throughout radiation therapy, high-energy x-rays are used to kill cancer cells. In advanced stages of colon cancer, radiation therapy is often given alternatively of surgery when an operation cannot be performed.


  • Track 4-1Intra-operative radiation therapy (IORT)
  • Track 4-2External beam radiation therapy (EBRT)
  • Track 4-3Intensity Modulated Radiation Therapy (IMRT)
  • Track 4-4Radio-embolization
  • Track 4-5Endocavitary Radiation therapy

Lynch syndrome or Hereditary Nonpolyposis Colorectal Cancer (HNPCC) is an autosomal dominant genetic state that is integrated with a high risk of colon cancer as well as other cancers including endometrial cancer (second most common), small intestine, hepatobiliary tract, ovary, stomach, brain, skin and upper urinary tract.


  • Track 5-1Colon Polyps
  • Track 5-2Immunohistochemistry (IHC)
  • Track 5-3Microsatellite instability (MSI)
  • Track 5-4MLH1 & MSH2 gene
  • Track 5-5MSH6, PMS2, and EPCAM (Epithelial Cell Adhesion Molecule)

Inflammatory bowel diseases such as Crohn disease or ulcerative colitis are incorporated with colorectal cancer, as is the presence of a large amount of noncancerous polyps along the wall of the colon or rectum. The earliest phases of colorectal tumorigenesis initiate in the normal mucosa, with a generalized disorder of cell replication, and with the appearance of clusters of enlarged crypts (aberrant crypts) showing proliferative, biochemical and biomolecular abnormalities. The larger part of colorectal malignancies initiate from adenomatous polyps. These can be explained as well demarcated masses of epithelial dysplasia, with uncontrolled crypt cell separation. An adenoma can compare malignant when neoplastic cells pass through the muscularis mucosae and infiltrate the submucosa.

  • Track 6-1Adenocarcinoma in situ
  • Track 6-2Adenocarcinoma
  • Track 6-3Medullary carcinoma
  • Track 6-4Mucinous carcinoma
  • Track 6-5Signet ring cell carcinoma
  • Track 6-6Squamous cell (epidermoid) carcinoma
  • Track 6-7Adenosquamous carcinoma
  • Track 6-8High grade neuroendocrine carcinoma

Tumor is an unusual growth of cells that serves no objective. Benign tumor is not a malicious tumor, which is cancer. Most colonic tumors are benign epithelial polyps. Growth of a benign tumor might be linked to Environmental toxins, such as exposure to radiation, Inflammation or infection, Diet and Stress, Local trauma, injury, Genetics. Types of Benign Tumors include Adenomas and Fibromas.


  • Track 7-1Fecal Incontinence
  • Track 7-2Anal Sphincter
  • Track 7-3Rectal Prolapse
  • Track 7-4Retrospective Cohort Analysis
  • Track 7-5Irritable Bowel Syndrome (IBS)
  • Track 7-6Bowel Incontinence

Cancer cells may break away from a tumor in the colon or rectum and develop to other parts of the body through the lymphatic system or bloodstream. These cells may settle and form new tumors on a non- identical organ. Even though the cancer has spread to a new organ, it is still named after the part of the body where it initially started. So colorectal cancer that metastasizes, to the lungs, liver or any other organ is called metastatic colorectal cancer. The most common site of metastases for colon or rectal cancer is the liver.


  • Track 8-1Interventional Radiology
  • Track 8-2Chemotherapy for Metastatic Colorectal Cancer
  • Track 8-3Metachronous Disease
  • Track 8-4Non-resectable tumors
  • Track 8-5Resectable liver metastasis
  • Track 8-6Lymph Nodal Metastases

Screening for colon cancer, which is predominantly recommended for all people age 45 and older, can specify a problem, but it cannot precisely diagnose the disease. Instead, a diagnostic (rather than a screening) colonoscopy, biopsy, and imaging tests are needed to approve and define the extent of colon cancer. While many people start this action because of habitual recommended checks, others do so because of worrisome symptoms, an unusual physical examination, or a new finding on a lab test.

  • Track 9-1Diagnostic Colonoscopy
  • Track 9-2Biopsy
  • Track 9-3Computed tomography (CT or CAT) scan
  • Track 9-4Magnetic resonance imaging (MRI)
  • Track 9-5Positron emission tomography (PET) or PET-CT scan
  • Track 9-6Proctoscopy

A colectomy is surgery to cut all or part of the colon. Nearby lymph nodes are also removed. If only part of the colon is removed, it's called a hemicolectomy, segmental resection or partial colectomy. The surgeon takes out the part of the colon with the cancer and a small segment of normal colon on either side Surgery is often the main treatment for earlier-stage colon cancers. The type of surgery used depends on the stage of the cancer, where it is, and the aim of the surgery. The following are type of surgery included


  • Track 10-1 Laparoscopic surgery
  • Track 10-2Colostomy for rectal cancer
  • Track 10-3Radiofrequency ablation (RFA) or cryoablation
  • Track 10-4Local Excision
  • Track 10-5Anastomosis
  • Track 10-6Ablation and Embolization

All colorectal cancers induced by a transmitted mutation – a genetic change that can be progressed from parent to child. The major subtypes of congenital colon cancer and some rare conditions include an inherited risk for colorectal cancer. In some families if there is a strong hint or symptoms present genetically from ancestors, may pass that mutated gene from parent to offspring. The disease susceptibility of these families occurs unusually or by genetic mutations which might not been observed that easily because mutations occur in gene like APC, KRAS, TP53, SMAD4 THAT that lead cells to extend uncontrollably resulting in Colorectal Cancer. Genetic experts and physicians can help understand colorectal cancer risk and type.


  • Track 11-1History & family background
  • Track 11-2Familial adenomatous polyposis (FAP)
  • Track 11-3Hereditary nonpolyposis colorectal cancer (HNPCC)
  • Track 11-4Attenuated familial adenomatous polyposis (AFAP)
  • Track 11-5 Irritable Bowel Disease (IBD)
  • Track 11-6 Inherited Syndrome
  • Track 11-7Lynch Syndrome
  • Track 11-8Mutation Associated Polyposis
  • Track 11-9Peutz Jeghers Syndrome
  • Track 11-10MUTYH Associated Polyposis

Immunotherapy treatments can act as a catalyst or healer for ideal immunologic conditions that could increase the lives of colorectal cancer patients. The recent progress of certain Immune-tool help to classify tumors; recognize the rate of survival in patients with colorectal cancers, issuing precise diagnosis information that can improve the clinical decisions and treatment of patient. It is believed that if immunotherapy is used as cure not only in colorectal cancer but for other type of cancer diseases it will be a ray of hope for future medical research in diagnosing the disease quickly and to cure it. Some of the immunotherapy includes


  • Track 12-1Biological response modifiers
  • Track 12-2Colony stimulating factors
  • Track 12-3Tumor vaccines
  • Track 12-4Monoclonal antibodies

Colorectal sarcomas are a group of diversified tumors which can develop in blood vessels, smooth muscles, or other connective tissues in the inner lining of the colon and rectum. It is a very unusual type of cancer; only 0.1% of all colorectal cancers are colorectal sarcomas. Of all colorectal sarcomas, 25.4% develop in the rectum 70.7% develop in the colon, and 3.9% are located in the rectosigmoid region.


  • Track 13-1Colorectal Adenocarcinoma
  • Track 13-2Colorectal Neoplasm
  • Track 13-3Leiomyosarcoma
  • Track 13-4Histiocytomas
  • Track 13-5Desmoplastic
  • Track 13-6Gastrointestinal Stromal Tumor (GIST)

The therapy of colorectal cancer patients is often unsuccessful because of the presence of cancer stem cells (CSCs) resistant to conventional perspective. Dendritic cells-based protocols are maintained to effectively supplement CRC therapy. Comparable methods were introduced with the use of CRC HCT116 and HT29 cell lines. We found that the detailed arrangement of CSC-like markers remarkably influenced the maturation and activation of DCs after stimulation with cancer cells lysates or culture supernatants.


  • Track 14-1Quiescent Intestinal Stem Cell Markers
  • Track 14-2Stem Cell Phenotype in Colon Cancer
  • Track 14-3Intestinal Stem Cell
  • Track 14-4Cell Surface CSC Markers

A variety of genetic and molecular alterations underlie the development and progression of Colorectal Neoplasia (CRN). Most of these cancers arise sporadically due to multiple somatic mutations and genetic variability. Genetic instability includes chromosomal variability and microsatellite uncertainty, which is observed in most genetic non-polyposis colon cancers (HNPCCs) and accounts for a small proportion of sporadic CRN. Many biomarkers have been utilized in the diagnosis and prediction of the clinical outcomes of CRNs. New markers and genes related with the expansion and progression of CRNs are being discovered at an accelerated rate. CRN is a heterogeneous disease, mainly with respect to the anatomic position of the tumor, race/ethnicity differences, and genetic and dietary interactions that influence its development and progression and act as confounders.


  • Track 15-1Sporadic CRNs
  • Track 15-2Invasive Neoplasia
  • Track 15-3Lesions of CRNs
  • Track 15-4Hereditary CRNs (Colorectal Cancer Neoplasia)

The colorectal cancer varies in different world regions. The highest colorectal cancer is noted in industrialized countries, and in developing countries Colorectal cancer is not diagnosed high. The number of colorectal cancer cases increases in countries that undergo rapid economic transformations and adopt a Western lifestyle.  This observation strongly suggests that one of the key mechanisms of carcinogenesis of colorectal cancer is associated with environmental factors. All cancer treatment is based on stages as each stage has their own variation. In Colorectal Cancer, this variation or treatment is determined by stages only which is divided to ‘TNM’-TUMOR, NODE, METASTASIS combination of this three will determine the stage of Colorectal Cancer which initially begins at stage 0 to stage 5. Tumor varies from T0-T4B, similarly for the node also NX to N2B and metastasis is MX-M1B.


  • Track 16-1Stage 0
  • Track 16-2 Stage I
  • Track 16-3Stage II A
  • Track 16-4Stage II A
  • Track 16-5Stage II A
  • Track 16-6Stage III A
  • Track 16-7Stage III B
  • Track 16-8Stage III C
  • Track 16-9Stage IV A
  • Track 16-10Stage IV B

Experiment proofs suggest that lactic acid bacteria may be protective against the development and progression of colorectal cancer through several mechanical functions like antioxidant, immune-modulation, programmed cell death and epigenetic modification of cancer cells. Massive-scale genome progression studies have been done to recognize mutations in colorectal cancer patients' genome.


  • Track 17-1The cancer genome Atlas
  • Track 17-2Mouse model of colorectal cancer
  • Track 17-3Aspirin Drug
  • Track 17-4Oncotype Dx Screening
  • Track 17-5Colon Cancer Assay
  • Track 17-6Coloprint Dx
  • Track 17-7Immune Checkpoint Inhibitors
  • Track 17-8Cancer Vaccines
  • Track 17-9Hyperthermic Intraperitoneal Chemotherapy

Chemotherapy is a treatment that uses various drugs and medication to pause the growth of tumor cells, by destructing or by stopping the division of tumor cell. The chemotherapy is taken by mouth or injected into vein or muscle, the drugs reach the bloodstream and cancer cells throughout the body. Chemotherapy can also be done through applying the drugs directly on effected region or via cerebral fluid. Only a small amount of the drug reaches other parts of the body. The way chemotherapy is given, depends on the type and stage of the colorectal cancer being treated. There are different chemotherapy drugs for treatment of colorectal cancer. 

  • Track 18-1Capecitabine (Xeloda)
  • Track 18-2 Irinotecan (Camptosar)
  • Track 18-3Trifluridine/tipiracil (TAS-102, Lonsurf)
  • Track 18-4 Irinotecan
  • Track 18-55-FU with leucovorin and oxaliplatin (FOLFOX)
  • Track 18-6Systemic Chemotherapy
  • Track 18-7Regional Chemotherapy
  • Track 18-8Adjuvant Chemotherapy
  • Track 18-9 NeoAdjuvant Chemotherapy